5 completed. 5 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 5 |
| Phase 2 | 3 | Completed 3 |
Follow Alopecia universalis: new trials by email Literature Review of Alopecia universalis trials Research Report on Alopecia universalis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi. Tofacitinib - Alopecia Areata, Alopecia Totalis | Phase 3 | Completed | Jinnah Hospital | 30 | 2023-07-01 | 2024-02-26 |
| Long-Term PF-06651600 for the Treatment of Alopecia Areata PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine - Alopecia Areata | Phase 3 | Completed | Pfizer | 1057 | 2019-07-18 | 2026-04-09 |
| PF-06651600 for the Treatment of Alopecia Areata PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2 - Alopecia Areata | Phase 2 / Phase 3 | Completed | Pfizer | 718 | 2018-12-03 | 2022-02-24 |
| The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Botulinum toxin A, Normal saline injection - Recalcitrant Alopecia Totalis, Recalcitrant Alopecia Universalis | Phase 2 / Phase 3 | Completed | Siriraj Hospital | 20 | 2009-12-01 | 2012-08-02 |
| Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata Targretin Gel 1% - Alopecia Areata | Phase 2 / Phase 3 | Completed | M.D. Anderson Cancer Center | 46 | 2003-05-01 | 2012-08-02 |
Alopecia Areata (4) · Alopecia (2) · Hair Diseases (1)
Hypotrichosis (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Hair Diseases (3) · Alopecia (2) · Pathological Conditions, Anatomical (2) · Pathological Conditions, Signs and Symptoms (2)
Bexarotene (1) · Botulinum Toxins, Type A (1) · PF-06651600 (1) · Saline Solution (1) · Tetanus Toxoid (1) · Vaccines (1) · tofacitinib (1)
Pfizer (2) · Jinnah Hospital (1) · M.D. Anderson Cancer Center (1) · Siriraj Hospital (1)
United States (3) · Argentina (2) · Australia (2) · Canada (2) · Chile (2) · China (2) · Colombia (2) · Czechia (2) · Germany (2) · Japan (2) · Mexico (2) · Poland (2) · Russia (2) · South Korea (2) · Spain (2)
Madeleine Duvic, MD (1) · Rasthawathana Desomchoke, MD (1) · Rattapon Thoungtong, MD (1) · Supenya Varothai, MD (1) · Suthasinee Pattaravadee, B.Sc (1)
PMID 38263353, PMID 39962358, PMID 41917311, PMID 42481842, PMID 42823604, PMID 24940651, PMID 28139263, PMID 28300084, PMID 29273099, PMID 31799258, PMID 34211288, PMID 36177791, PMID 37062298, PMID 37339501, PMID 37403610, PMID 37521227, PMID 37707764, PMID 37917289, PMID 37955531, PMID 39254890, PMID 39328096, PMID 39423930, PMID 39432738, PMID 39441519, PMID 39846397, PMID 40261547, PMID 41005700, PMID 41579233, PMID 41645877
2018 (1), 2023 (1)